Feasibility of Fluorescence Imaging with Bevacizumab-800CW During Bronchoscopy

Inclusion Criteria

• •1. Signed informed consent prior to participation in the study.
• •2. Age ≥ 18 years.
• •3. Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule - with or without pathological lymph nodes - which is considered malignant (independent of its primary origin).
• •4. Patient is considered fit to undergo a diagnostic and/or therapeutic bronchoscopy (with or without addition of virtual navigation and/or endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.